Newsletter Signup | Join Community
Tagrissio, Tarceva and other TKI therapy for EGFR + NSCLC continue to evolve and improve survival.
PCI may improve survival in small cell lung cancer; new study suggests some benefit in early stage NSCLC.
Liquid biopsy improves access to precision cancer medicines and expands NSCLC treatment options.
Initial treatment with the Keytruda checkpoint inhibitor immunotherapy has become a standard of care for PD-1 + NSCLC.
The precision cancer medicine Tarceva targeting EGFR improves survival in stage I-III NSCLC & appears better than chemo!
Lung-MAP Precision Medicine Clinical Trial expanded to include all types of NSCLC including squamous and adenocarcinoma.
Stay Current With Lung Cancer Treatment Advances & Connect with Others
Genomic testing for "emerging biomarkers" like HER, MET and RET will become increasingly important for managing NSCLC.
Chemotherapy, biomarker testing and precision cancer medicines and immunotherapy are part of recurrent NSCLC treatment.
Lung cancer is occurring more frequently in women: understand the causes and what can you do to lower your risk.
Tarceva™ Improves Survival in Non-Small Cell Lung Cancer
HER 2 + Lung Cancer Treatment? https://coloradocancerblogs…
Dana Farber and MDACC discover why anti-PD 1 immunotherapy doesnt work in some patients and work to…
High incidence of ROS 1 false negative tests reported by U Colorado researchers. http://www…